We just sent you a verification email. Please verify your account to gain access to MedTech Unplugged, the Future of AI in Healthcare & Life Sciences. If you don’t think you received an email check your spam folder.
In order to sign in, enter the email address you used to registered for the event. Once completed, you will receive an email with a verification link. Open this link to automatically sign into the site.
Please fill out the information below. You will receive an email with a verification link confirming your registration. Click the link to automatically sign into the site.
We just sent you a verification email. Please click the verification button in the email. Once your email address is verified, you will have full access to all event content for theCUBE + NYSE Wired: MedTech Unplugged, the Future of AI in Healthcare & Life Sciences.
Thanks for confirming your account. Now you can access theCUBE + NYSE Wired: MedTech Unplugged, the Future of AI in Healthcare & Life Sciences with this email address.
We just sent you a verification email. Please verify your account to gain access to MedTech Unplugged, the Future of AI in Healthcare & Life Sciences. If you don’t think you received an email check your spam folder.
In order to sign in, enter the email address you used to registered for the event. Once completed, you will receive an email with a verification link. Open this link to automatically sign into the site.
Please sign in with LinkedIn to continue to MedTech Unplugged, the Future of AI in Healthcare & Life Sciences. Signing in with LinkedIn ensures a professional environment.
By proceeding, you acknowledge that you have read and agreed to CUBE365 Privacy Policy and Terms of Service.
How would you rate this session?
Feedback
Exploring the MedTech Landscape: Kevin Reilly Discusses Innovations and Trends
Kevin Reilly, managing director and head of medtech at Ally Bridge Group, joins the inaugural MedTech Unplugged Series hosted by theCUBE and NYSE Wired. This series initiates discussions around the integration of artificial intelligence and other emerging technologies in healthcare, examining the expansive potential for growth and innovation in the medical technology sector.
In this episode, Reilly provides insights into Ally Bridge Group's dedicated focus on healthcare investments, managing a capital range of $1.5 billion to $2 billion. Specializing in life sciences, the group invests in biotechnology, medical technology, and digital health. Hosted by theCUBE's John Furrier and featuring insights from theCUBE Research analysts, the discussion explores integrated technologies such as AI and robotics and the challenges of scaling innovative medical devices in a highly regulated industry.
Viewers will gain an understanding of how medical technology companies such as Ally Bridge harness cutting-edge technology to enhance patient monitoring, improve disease detection, and provide better outcomes for patients. Reilly explains that despite the stringent regulatory landscape, the medical technology sector experiences positive momentum with a resurgence in initial public offering activities, highlighting the growing interest in high-growth market opportunities driven by innovations in robotics and AI.
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly
Kevin Reilly